<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Incretin-based therapies, including glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, are the latest addition to the range of available medications for the management of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The GLP-1 analog liraglutide has been approved for use in Europe and the US for over a year and has undergone evaluation in several pharmacokinetic/pharmacodynamics studies and in an extensive phase 3 clinical program </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Data are presented from the pharmacokinetics/pharmacodynamics studies of liraglutide and from nine published phase 3 studies, including the six Liraglutide Effect and Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> (LEAD) studies </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Liraglutide is effective at improving indices of glycemic control, and has a good tolerability and safety profile </plain></SENT>
<SENT sid="5" pm="."><plain>Beneficial effects on weight (mean reduction of 1-3.4 kg) and blood pressure (systolic blood pressure decreased by 2.1-6.7 mmHg) are also observed </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Liraglutide is an effective and well tolerated option for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>